CCL19

Chr 9

C-C motif chemokine ligand 19

NCBI Gene: 6363ENSG00000172724UniProt: Q99731

May play a role not only in inflammatory and immunological responses but also in normal lymphocyte recirculation and homing. May play an important role in trafficking of T-cells in thymus, and T-cell and B-cell migration to secondary lymphoid organs. Binds to chemokine receptor CCR7. Recombinant CCL19 shows potent chemotactic activity for T-cells and B-cells but not for granulocytes and monocytes. Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4

94
ClinVar variants
0
Pathogenic / LP
0.32
pLI score
2
Active trials
Clinical Summary— CCL19
⚡
Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.24) despite low pLI — interpret in context.
📋
ClinVar Variants
94 total variants — no pathogenic classifications of 94 total submissions
💊
Clinical Trials
2 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD
Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.13LOEUF
pLI 0.317
Z-score 1.44
OE 0.24 (0.08–1.13)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
1.15Z-score
OE missense 0.57 (0.43–0.77)
33 obs / 57.4 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.24 (0.08–1.13)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.57 (0.43–0.77)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.46
0≤1.21.6
LoF obs/exp: 1 / 4.2Missense obs/exp: 33 / 57.4Syn Z: 1.95

ClinVar Variant Classifications

94 submitted variants in ClinVar

ClinVar

Classification Summary

Protein Context — Lollipop Plot

CCL19 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

OMIM
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis.
Zhang Y et al.·Cancer Cell
2024
Spatial transcriptomics combined with single-cell RNA-sequencing unravels the complex inflammatory cell network in atopic dermatitis.
Mitamura Y et al.·Allergy
2023
Skin immune-mesenchymal interplay within tertiary lymphoid structures promotes autoimmune pathogenesis in hidradenitis suppurativa.
Yu WW et al.·Immunity
2024
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.
Pang N et al.·J Hematol Oncol
2021Clinical trial
GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy.
Lu LL et al.·Cell Biol Toxicol
2023
A single-cell and spatial genomics atlas of human skin fibroblasts reveals shared disease-related fibroblast subtypes across tissues.
Steele L et al.·Nat Immunol
2025
CCL19(+) dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer.
Wu SY et al.·Med
2023
Spatial maps of hepatocellular carcinoma transcriptomes reveal spatial expression patterns in tumor immune microenvironment.
Wang YF et al.·Theranostics
2022
Spatially resolved atlas of breast cancer uncovers intercellular machinery of venular niche governing lymphocyte extravasation.
Wang X et al.·Nat Commun
2025
Fibroblast Subpopulations in Systemic Sclerosis: Functional Implications of Individual Subpopulations and Correlations with Clinical Features.
Zhu H et al.·J Invest Dermatol
2024Functional
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC
CAR-T cells co-expressing IL-7 and CCL19 promote epitope spreading to enhance antitumor immunity.
Adachi K et al.·Cancer Immunol Immunother
2026🔓 Open Access
CCR-CCL axes as key upstream influencers of pancreatic ductal adenocarcinoma: CCR2-CCL2, CCR5-CCL5, CCR4-CCL17/22, CCR6-CCL20, CCR7-CCL19/21.
Bahng I.·Front Immunol
2026🔓 Open Access
Enhancement of B7-H3 chimeric antigen receptor-T cell efficacy via the coexistence effect of IL-7, IL-15 and CCL19 for pancreatic and lung xenograft tumors.
Zhang Q et al.·Biochem Pharmacol
2026
CCL19+ fibroblast-CCR7+ T-cell crosstalk coordinates immunofibrotic signalling networks in systemic sclerosis.
Guo W et al.·Br J Dermatol
2026
miR-7213-5p-mediated suppression of CCL19 in fibroblast cells may attenuate lupus nephritis.
Gao Z et al.·Clin Exp Med
2025🔓 Open Access
Top 5 resultsSearch Europe PMC ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov
Hepatocellular CarcinomaImmunotherapyCAR

GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression

RECRUITING
NCT03198546Phase PHASE1Second Affiliated Hospital of Guangzhou Medical UniversityStarted 2017-07-01
GPC3 and/or TGFβ targeting CAR-T cells
Prostate CancerProstate Inflammation

Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage

ENROLLING BY INVITATION
NCT06505356Phase NAEdgaras BurzinskisStarted 2024-09-01
Prostate biopsy

External Resources

Links to major genomics databases and tools